

Short CV with photo Frédéric Amant

Dear President,

It is with great enthusiasm that I write this motivation letter for the upcoming ESGO council elections. Ten years ago, I had the honor to serve the ESGO society as council member. Today, it is my ambition to further built on that experience and improve my contribution with an added layer of (age induced) wisdom.

The integration of the many novel research data into clinical practice, the migration challenge and the climate change require our creativity and flexibility. If elected, I will use my enthusiasm and inspiration to help the ESGO society overcome these challenges. In addition, colleagues and patients from Eastern Europe face particular problems that deserve our commitment.

Some projects are closer to my personal sphere. The International Network of Cancer, Infertility and Pregnancy (INCIP), that I founded in 2005, will continue to address new clinically relevant questions. Today, we launched the Advisory Board for Cancer, Infertility and Pregnancy (ABCIP), an online tool that aims to advice clinicians over the world in the clinical management of pregnant cancer patients. Through INCIP, we will also spearhead our fertility preservation research. Further, the ambition of the European Network for Individualised Treatment of Endometrial Cancer (ENITEC), that I co-founded in 2011, is to further invest in endometrial cancer translational research to assist in the development of clinical guidelines.

With your support, I will be able to pursue this program that will run in parallel with other existing ESGO projects that are beneficial for our patients, our society and its members.

You can count on me,

Frédéric Amant



Frédéric Amant (MD, PhD) (°1967) received his medical degree from the University of Leuven (KU Leuven), Belgium, in 1992 and completed his specialty training in Obstetrics and Gynecology in Leuven, Pretoria (South Africa) and Concepción (Chile) in 1998. He completed his subspecialty training in Gynecologic Oncology in Pretoria and Leuven in 2000. He pioneered the sentinel lymph node biopsy in breast cancer and the nerve sparing radical hysterectomy at UZ Leuven. He is professor at the KU Leuven, and at the University of Amsterdam, the Netherlands, and honorary professor at the University of Pretoria, South Africa. He is specialist at the Netherlands Cancer Institute in Amsterdam.

Frédéric Amant heads the Gynecologic Oncology research section at the University of Leuven and at the Netherlands Cancer Institute. In 2005, he founded the ESGO taskforce on Cancer in Pregnancy, now the “International Network on Cancer, Infertility and Pregnancy” (INCIP) (www.cancerinpregnancy.org), and chairs this network up until now. Since 2014, INCIP also registers young women who aim to preserve their fertility. At the KU Leuven, he founded the fund for Innovative Cancer Research, a platform that funds oncologic projects for teams at this institution. In addition, Frédéric Amant founded TRACE, the tumor xenograft platform at the KU Leuven, which bridges basic research closer and the clinic. He co-founded ENITEC, the European Network on Individualized Treatment of Endometrial Cancer. He has authored 555 PubMed publications, in journals such as NEJM, Nature, the Lancet journals, JAMA Oncology and the Journal of Clinical Oncology, which add to his H-index of 71.